Sodium-glucose co-transporter-2 (SGLT2) inhibitors rapidly reduce cardiovascular risk in patients with heart failure (HF)1–3, but underlying mechanisms have remained incompletely understood4,5. Here, SLC5A2 is linked to heart failure.